{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:37Z","timestamp":1786119277786,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/lgt.0b013e3181ac05e9","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T10:47:58Z","timestamp":1261392478000},"page":"29-36","source":"Crossref","is-referenced-by-count":47,"title":["Incidence and Costs of Cervical Intraepithelial Neoplasia in a US Commercially Insured Population"],"prefix":"10.1097","volume":"14","author":[{"given":"Henry J.","family":"Henk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph P.","family":"Insinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet K.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Darkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R2-5-20210126","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.vaccine.2005.09.001","article-title":"Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"R3-5-20210126","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1055-9965.355.13.3","article-title":"Pap screening in a U.S. health plan.","volume":"13","author":"Insinga","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R4-5-20210126","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00218-0","article-title":"Young women, cervical intraepithelial neoplasia and human papillomavirus: risk factors for persistence and recurrence.","volume":"196","author":"Frega","year":"2003","journal-title":"Cancer Lett"},{"issue":"suppl 1","key":"R5-5-20210126","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/01.gco.0000216315.72572.fb","article-title":"The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?","volume":"18","author":"Cox","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R6-5-20210126","first-page":"17","article-title":"Cervical human papillomavirus infection and intraepithelial neoplasia: a review.","volume":"21","author":"Mitchell","year":"1996","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R7-5-20210126","first-page":"347","article-title":"Cervical intraepithelial neoplasia and cervical cancer.","volume":"23","author":"Morris","year":"1996","journal-title":"Obstet Gynecol Clin"},{"key":"R8-5-20210126","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"R9-5-20210126","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"for the Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine.","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"R10-5-20210126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study.","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R11-5-20210126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus-related disease.","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R12-5-20210126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006250-200008000-00012","article-title":"Frequency of cervical smear abnormalities within 3 years of normal cytology.","volume":"96","author":"Sawaya","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R13-5-20210126","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0889-8545(02)00045-1","article-title":"Use of visual screening methods for cervical cancer screening.","volume":"29","author":"Wright","year":"2002","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"suppl","key":"R14-5-20210126","first-page":"3","article-title":"Epidemiology and natural history of HPV.","author":"Cox","year":"2006","journal-title":"J Fam Pract"},{"key":"R15-5-20210126","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"R16-5-20210126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R17-5-20210126","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","article-title":"Cost-effectiveness analyses of human papillomavirus vaccination.","volume":"7","author":"Newall","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R18-5-20210126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"key":"R19-5-20210126","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.288.14.1749","article-title":"Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.","volume":"288","author":"Kulasingam","year":"2002","journal-title":"JAMA"},{"key":"R20-5-20210126","first-page":"223","article-title":"Solomon D, for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.","volume":"11","author":"Wright","year":"2007","journal-title":"Am J Obstet Gynecol"}],"container-title":["Journal of Lower Genital Tract Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00128360-201001000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:03Z","timestamp":1786039803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00128360-201001000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/lgt.0b013e3181ac05e9","relation":{},"ISSN":["1089-2591"],"issn-type":[{"value":"1089-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}